Latest Ratios: P/E Ratio -2.1x · EV/EBITDA N/A · ROE -54.4%. (2022–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $66M | $149M | $99M | — | — |
| Enterprise Value | $66M | $149M | $103M | — | — |
| P/E Ratio → | -2.09 | — | — | — | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | 1.16 | 3.32 | 2.16 | — | — |
| P/FCF | — | — | 787.17 | — | — |
| P/OCF | — | — | 787.14 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | 817.24 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | -54.4% | -54.4% | -59.0% | -41.1% | -30.0% |
| ROA | -26.7% | -26.7% | -32.0% | -28.1% | -25.5% |
| ROIC | -37.3% | -37.3% | -40.9% | -29.4% | -20.1% |
| ROCE | -45.6% | -45.6% | -52.5% | -38.2% | -26.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.08 | 0.08 | — | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.00 | 0.08 | 0.00 | 0.00 |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | 30.08 | — | — |
| Interest Coverage | -107.72 | -107.72 | — | — | — |
Net cash position: cash ($4M) exceeds total debt ($4M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 0.56 | 0.56 | 0.34 | 0.37 | 0.46 |
| Quick Ratio | 0.11 | 0.11 | 0.08 | 0.37 | 0.46 |
| Cash Ratio | 0.08 | 0.08 | 0.00 | — | — |
| Asset Turnover | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | 0.1% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $73M | $72M | $89M | $90M |
Imminent liquidity shortfall
As reported in recent financial statements, CTOR's gross margin of 80.3% in 2026Q2 highlights the premium pricing potential of its orphan oncology asset, yet the negative operating margin of 17.2% underscores the significant burden of commercial infrastructure costs relative to current revenue generation levels.
The high gross margin reflects the inherent value of the LYMPHIR biologic, but the inability to translate this into positive operating income suggests that the company is currently in a high-burn phase. Investors should monitor whether the company can achieve sufficient patient volume to leverage these fixed costs, as the current margin profile appears unsustainable without a substantial increase in top-line scale.
Based on the company's 2026Q2 reported figures, the ROIC of -47.0% indicates a severe destruction of invested capital, reflecting the company's struggle to generate returns while simultaneously funding the intensive commercialization efforts required for its niche oncology therapeutic in a competitive market environment.
The negative return on capital is a direct consequence of the substantial operating losses incurred during the launch phase. This trend warrants further investigation into whether the company's capital allocation strategy can pivot toward profitability before the existing capital base is fully exhausted by ongoing operational deficits.
According to quarterly data, the asset turnover ratio of 0.02 in 2026Q2 reveals a significant lack of operational efficiency, as the company's asset base remains largely unproductive while it navigates the early stages of its commercial rollout for its primary oncology asset.
The extremely low turnover ratio suggests that the company's capital is tied up in non-productive assets or that the revenue base is too small to justify the current asset intensity. The high cash conversion cycle, driven by significant inventory and receivable management challenges, indicates that the company faces structural hurdles in optimizing its working capital.
As indicated by the 2026Q2 balance sheet, the current ratio of 0.50 and a quick ratio of 0.12 demonstrate a highly vulnerable liquidity position, leaving the firm with minimal financial flexibility to meet its short-term obligations without immediate access to additional external capital.
The reliance on external financing is evident given the rapid depletion of cash reserves. Investors should monitor the company's ability to secure non-dilutive funding or strategic partnerships, as the current liquidity profile suggests that the firm is at high risk of insolvency if the commercial launch does not accelerate rapidly.
The P/B ratio of 1.01 is frequently misapplied to CTOR, as it obscures the reality that the company's book value is heavily comprised of intangible assets rather than tangible productive capacity, thereby providing a false sense of security regarding the company's underlying asset-backed valuation.
Using book value as a floor for valuation is misleading for a pre-scale biotech firm where the primary value is tied to regulatory exclusivity and intellectual property. Analysts should instead focus on cash burn rates and the probability-adjusted net present value of the drug's future cash flows to better assess the company's true economic worth.
Includes 30+ ratios · 4 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CTOR stock.
Citius Oncology, Inc.'s current P/E ratio is -2.1x. This places it at the 50th percentile of its historical range.
Citius Oncology, Inc.'s return on equity (ROE) is -54.4%. The historical average is -46.1%.
Based on historical data, Citius Oncology, Inc. is trading at a P/E of -2.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.